Next Investors logo grey

Tax furore as Pfizer clinches $160BN deal with Allergan

Published 24-NOV-2015 12:03 P.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Pfizer, the second biggest pharmaceutical company in the world behind Novartis has embarked on a large scale acquisition of Botox producer Allergan.

The $160BN acquisition will place Pfizer as the world’s largest pharmaceutical business.

This deal follows a pattern in which the pharmaceutical industry has seen acquisitions totalling over $600Bn this year as the industry consolidates.

John Colley, Professor of Practice at Warwick Business School and an expert on large-scale mergers said of the deal, “Industry valuations increase as industry players become concerned at being left behind in the race for scale. In the instance of Pfizer it is also pursuing greater growth as its own established products are losing patent protection at a greater rate than it can produce innovative products.

“Allergan’s drug portfolio has greater potential for growth. In addition the lure of tax advantages from a Dublin Head Office has been a significant factor in driving this deal. The threat of succumbing to US tax rates has meant that Pfizer has been desperate for a deal outside the US. The failure of the AstraZeneca bid in a consolidating industry has driven the substantial price paid for Allergan.”

Next Investors Image

Lipitor: one of Pfizer’s biggest selling products.

The tax implications have been denounced by US presidential candidates including Bernie Sanders and Hilary Clinton.

It is one deal in an increasingly long line of US companies moving their head office overseas to exploit another country’s lower tax regime.

The move would headquarter Pfizer in Ireland where Allergan is based and its tax rate would drop below 20%

Clinton opposes tax inversions and would call on regulators to crack down.

“We cannot delay in cracking down on inversions that erode our tax base,” she said in a statement on Monday.

Meanwhile Sanders tweeted: “This merger would be a disaster for Americans who already pay the highest prices in the world for prescription drugs.”

“In a year in which low interest rates, relatively benign markets, reasonable growth prospects and institutions awash with cash there is likely to be a record number of deals exceeding the previous record of $4.6 Trillion in 2007,” Colley said.

“Most deals this year have been consolidations within an industry which have a clear strategic logic and as a consequence slightly lower risk. AB InBev and SAB Miller, Dell and EMC, Holcim and Lafarge are designed to exploit greater market power through size and generate substantial cost savings through scale and scope economies. Head Office and Regional management are generally key targets.

“Both institutions and businesses draw confidence from ‘strength in numbers’ which encourages more deals. Despite the enormous risks associated with acquisitions in which over half destroy value and 60 to 80% materially fail to deliver expected benefits the rush goes on.”

Colley feels that many companies are paying too much for their acquisitions.

“Research shows that the biggest reason for acquisitions failing to deliver benefits is simply paying too much! One wonders how many of the 2015 deals will ultimately fail to deliver value. My money is on more than half.”

Time will tell whether Pfizer will benefit from this deal with Allergan.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.